射频消融术联合索拉菲尼治疗原发性肝癌的效果观察

摘要

目的 探讨射频消融术联合索拉菲尼治疗原发性肝癌的效果.方法 选取2011年1月至2012年7月山西省人民医院收治的原发性肝癌患者90例,按入院时间顺序分为对照组和观察组,各45例.对照组给予肝癌射频消融术治疗,观察组给予肝癌射频消融术联合索拉菲尼(400 mg/次,2次/d,饭后2h口服)治疗.比较2组患者射频消融间隔时间,总有效率,治疗第6、12个月及第3年的生存率.结果 观察组射频消融间隔时间明显长于对照组[(5.2±1.2)个月比(3.9±1.3)个月]、总有效率明显高于对照组[60.0％ (27/45)比33.3％(15/45)]、治疗第6、12个月及第3年生存率均明显高于对照组[75.6％(34/45)比38.9％ (22/45),37.8％ (17/45)比11.1％ (5/45),22.2％ (10/45)比6.7％ (3/45)],差异均有统计学意义(均P ＜0.05).结论 肝癌射频消融术联合索拉菲尼治疗原发性肝癌效果良好.%Objective To explore the effect of radiofrequency ablation combined with sorafenib in treating primary hepatocellular carcinoma.Methods Totally 90 patients with primary hepatocellular carcinoma from January 2011 to July 2012 were sequentially divided into control group (45 cases) receiving radiofrequency ablation and observation group (45 cases) receiving radiofrequency ablation combined with sorafenib (400 mg/time,2 times/d).The time interval between two times of ablation,totally effective rate,survival rates 3,6 months and 3 years after treatment were compared between groups.Results The time interval between two times of ablation in observation group was significantly longer than that in control group [(5.2 ± 1.2) months vs (3.9 ± 1.3) months] (P ＜0.01);the total effective rate in observation group was significantly higher than that in control group [60.0％ (27/45) vs 33.3％ (15/45)] (P ＜ 0.05);the survival rates 6,12 months and 3 years after treatment in observation group were significantly higher than those in control group [75.6％ (34/45) vs 38.9％ (22/45),37.8％ (17/45)vs 11.1％ (5/45),22.2％ (10/45)vs 6.7％ (3/45)] (P＜0.05).Conclusion Radiofrequency ablation combined with sorafenib is effective in treating primary hepatocellular carcinoma.